Information Provided By:
Fly News Breaks for December 20, 2016
OMED
Dec 20, 2016 | 07:00 EDT
SunTrust analyst Peter Lawson initiated OncoMed with a Buy and a $16 price target saying positive data from Phase 2 data in pancreatic cancer and Phase 2 data in SCLC expected in 1H 2017, and Phase 1b data with demcizumab + Keytruda in 2H 2017 could drive shares higher. Lawson believes shares are udnervalued and expects near-term data to restore confidence in the stock.
News For OMED From the Last 2 Days
There are no results for your query OMED
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.